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sometimes painful, in the evening or early night. Periodic leg
movements (PLM)may occur during sleep. These are characterized
by an extension movement of the hallux, dorsiﬂexion of the ankle
and sometimes knee ﬂexion and hip. The pathophysiology of RLS is
not fully understood.
Studies have shown an increased prevalence of RLS in patientswith
Spinal cord Injury (SCI) or Multiple Sclerosis.
Objective The diagnosis of spasticity or RLS in patients com-
plaining of repeated nocturnal spasms in patients initially seen in
consultation because of spasticity resisting to pharmacological
treatment.
Method Prospective study, from March 2014 to March 2015,
monocentric, in the MPR Service Hospital Raymond-Poincare´.
Inclusion criteria: age over 18 years, SCI, MS patients, with
nocturnal predominance spasms. Exclusion criteria: presence of
pressure sores, unable to achieve a polysomnogram.
Weekday hospital patients for predominantly nocturnal spasms
resistant to pharmacological treatment of spasticity orally or even
to intrathecal therapy (IT) IT baclofen, associated with sleep
disorders, underwent a polysomnography. If RLS exists, 0.18 mg of
pramipexolewas administered to the patient, followed by a control
polysomnography.
Results Eleven patients (5MS, 5 SCI and a patient with hereditary
spastic paraplegia) were included. All had polysomnography for
RLS. A signiﬁcant improvement was experienced on 10 patients,
with a important reduction PLM on polysomnography control,
after administration of pramipexole.
Discussion This pilot study shows that RLS may be a differential
diagnosis of spasticity. The presence of nocturnal or supine
position spasms, in patients with central nervous system lesions of
SCI or MS types must result in the research for RLS and test the
effect of dopamine agonists in the case of positive diagnosis.
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Objective To study the contribution of ultrasound to conﬁrm
clinically identiﬁed injection points and then identiﬁed with
electrostimulation.
Type of study Observational, descriptive, prospective.
Material and methods Fifteen patients having already received
botulinum toxin injections were included (30 injected muscles).
Two injectors realized the gesture with electrostimulation
followed by an echographic examination of the position of the
needle. Patients received treatment twice at a distance of at least 3
months. During the second injection, spasticity and GAS (goal
attentment scaling) were reassessed before proceeding.
Results Ultrasound conﬁrmed a concurring needle position in
80% of cases. Three discrepancies were observed in each series, one
in one of the two points of the brachii biceps muscle and the other
two on one of the two points of the brachial muscle. Spasticity
decreased in 60% of cases according to the Tardieu scale and in 40%
according to the Ashworth scale. GAS was at zero in 73.3% of cases.
Discussion This study showed that tracking with muscle
electrostimulation afforded less precision than with ultrasound.
Ultrasound helped for gesture accuracy and effectiveness. Spastic-
ity decreased more when the location was good. The injection of
botulinum toxin into the muscles with electrically stimulated
tracking coupled with ultrasound would appear as a complemen-
tary technique, the accuracy of the gesture being reinforced by
ultrasound and the presence ofmuscle tissue being conﬁrmedwith
electrostimulation.
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Background Intramuscular injections with botulinum neurotox-
in type A (BoNT-A) have become the ﬁrst-line treatment for most
patients with focal and multifocal spasticity. Multiple controlled
trials have demonstrated the safety and efﬁcacy of repeated BoNT-
A injections for patients with focal spasticity. However, there is a
lack of data on treatment approaches in real-life clinical practice
and data on which patients in this diverse population are most
likely to beneﬁt from BoNT-A treatment. The purpose of the
SPAsticity in PractiCE (SPACE) study is to understand how
physicians use BoNT in the long-term management of spasticity,
to evaluate the safety and efﬁcacy of treatment with BoNT-A in
‘‘real-life’’ clinical practice and to collect information on treating
physicians and their treatment preferences and decisions.
Methods SPACE is a prospective, non-interventional, open-label,
multicenter, multinational study (106 active sites in 9 countries).
Participants can receive any number of treatment sessions with
any BoNT-A product available in their country, at the discretion of
their physician according to individual patients’ needs and
physician’s routine clinical practice.
Results Internationally 756 patients aged  18 years were in-
cluded with spasticity of any aetiology who require BoNT-A
injections and who have not been previously treated with BoNT-A
or BoNT-B for any indication. In total, 106 active sites and
230 physicians were involved. In France, 126 patients were
included, 21 active sites and 24 physicians were involved. Results
show that most patients (66.4% overall) had post-stroke spasticity
and that the most important key treatment goals were improve-
ments of functionality (especially ‘‘in mobility’’ and ‘‘in dexterity
and reaching’’).
Conclusion SPACE will help to further deﬁne the role of BoNT-A
as part of a multimodal management approach for focal spasticity
and to improve patient treatment according their needs. Data
collected will help to identify challenges physicians face in
managing patients with focal spasticity.
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